Abstract:Mutations in the CCAAT/enhancer binding protein α (CEBPA) gene occur in approximately 10% of all acute myeloid leukaemia (AML) cases, where half of the mutations are biallelic CEBPA (bi CEBPA), which has now been acknowledged to be associated with a favourable prognosis.1-5 However, long-term follow-up of cytogenetically normal CEBPA-mutated AML showed that the 5-year and 10-year cumulative incidence of relapse (CIR) rates were 37%–40% and 45% respectively, in bi CEBPA AML patients.4, 6 Therefore, the rapid identification of high-risk relapse patients and pre-emptively treating patients with more aggressive therapies may improve survival. Between January 2012 and April 2020, 262 newly diagnosed bi CEBPA de novo AML patients were enrolled in six Chinese centres. A total of 149 patients (56.9%) were men. The median age of the patients at diagnosis was 40 years (range 16–79 years). Among the 260 patients who achieved complete remission (CR), 224 received intermediate-dose cytarabine-based chemotherapy and 36 received chemotherapy followed by allogeneic- haematopoietic stem cell transplantation (allo-HSCT) in first complete remission (CR1; human leukocyte antigen-identical sibling donor, n = 9; matched unrelated donor, n = 3; haploidentical related donor, n = 24) as post-remission therapy. Twenty-nine patients who relapsed after chemotherapy received allo-HSCT as salvage therapy. One hundred and twenty-four of the patients at Peking University have been reported previously.7 All patients provided informed consent, according to the procedures of the institutional review board of each centre and in accordance with the Declaration of Helsinki. The cut-off date for follow-up was 28 February 2021. Genomic DNA extraction, targeted gene list, quality control data, access number gene panel, targeted sequencing panel data, and sequencing depth definition have been described in detail.7 Survival functions were estimated using the Kaplan–Meier method and compared using the log-rank test. Competing risk analyses were used to calculate the CIR and non-relapse mortality using Grey's test to examine differences between the groups. Parameters with a p value of < 0.2 by univariate analysis, were entered into a multivariate analysis using a Cox proportional hazards model, to identify the statistically significant parameters associated with survival, and the Fine-Grey model for CIR. Data analyses were performed using SPSS, version 24.0 software (IBM Corporation) and GraphPad Prism 6 (GraphPad Software Inc.). R statistical software version 3.6.1 (http://cran.R-project.org) was used for the competing-risks analysis. With a median follow-up of 34 months (range 0.5–109) in all patients and 43.5 months (range 10–109 ) in the 209 survivors, 88 patients relapsed at the median follow-up of 10.5 months (range 3–38). At the 5-year follow-up, the probabilities of CIR, relapse-free survival (RFS), and overall survival (OS) were 38.0%, 58.8%, and 75.7% respectively [with a 95% confidence interval (CI) of 34.7–41.3, 55.5–62.1, and 72.6–78.8 respectively]. Of these, 257 patients were analysed further by a sensitive next-generation sequencing (NGS) assay for mutations in 87 candidate genes and target regions. The cohort from the earlier study is seen as the training cohort (n = 124),7 the extra patients included in this study serve as the confirmation cohort (n = 138), the patient characteristics are comparable and shown in Table 1. Forty-nine other molecular mutations were detected in the patients with bi CEBPA. Sixty-two patients (24.1%) had no additional molecular mutation, while 100 (38.9%), 50 (19.5%), 26 (10.1%), 10 (3.9%), two (0.8%), and seven (2.7%) had one, two, three, four, five, and six or more additional mutations, respectively. The most common co-occurring mutations were found in the GATA2 (n = 64/257, 24.9%), WT1 (n = 57/257, 22.3%), CSF3R (n = 40/257, 15.6%), NRAS (n = 37/257, 14.4%), and TET2 (n = 28/257, 10.9%) genes. Without additional molecular mutations, the GATA2 mutation had good trends for lower CIR and longer RFS, the WT1 mutation had a poor factor for 5-year CIR (49.6% vs. 33.3%, p = 0.011), and 5-year RFS (48.1% vs. 63.5%; p = 0.017), and the CSF3R mutation had an inferior trend for higher CIR and shorter RFS. Patients without additional molecular mutations and with a GATA2 mutation were defined as “NGS low risk” (n = 92, 40.4%), while those with other co-occurring mutations were defined as “NGS high risk” (n = 136, 59.6%). Low-risk NGS had a favourable factor for 5-year CIR (28.8% vs. 43.0.8%, p = 0.042), 5-year RFS (69.4% vs. 53.4%; p = 0.021), and 5-year OS (82.2% vs. 68.9%, p = 0.026) (Figure 1). Minimal residual disease (MRD) was negative at the median follow-up of 2 months (range 1–7) Patients with positive MRD status after two consolidation cycles, and MRD-negative status lost at any time, had a higher CIR (5-year CIR, 62.3% vs. 31.0%; p < 0.001; 79.3% vs. 13.7%; p < 0.001 respectively) and worse RFS and OS (5-year RFS, 33.9% vs. 66.0%; p <0.001; 19.5% vs. 82.0%; p < 0.001 respectively; 5-year OS, 61.0% vs. 80.5%; p = 0.002; 61.1% vs. 88.5%; p < 0.001 respectively) than those with persistent negative MRD status. Patients with positive MRD status after two consolidation cycles and/or MRD-negative status lost at any time, were defined as “MRD high risk”, while those with persistent negative MRD status were defined as “MRD low risk.” Low-risk MRD was a favourable factor for 5-year CIR (13.4% vs. 83.9%, p < 0.001), 5-year RFS, (82.1% vs. 14.9%, p < 0.001), and 5-year OS (88.6% vs. 52.8%, p < 0.001) (Figure 1). Allo-HSCT after CR1 was a favourable factor for CIR (5-year CIR 6.8% vs. 42.4%; p < 0.001) and RFS (5-year RFS 81.6% vs. 55.6%, p = 0.010). For the relapse patients who obtained molecular remission during therapy, the median time was 3.5 months (range 0–22) from molecular relapse to clinical relapse. Patients with persistent positive MRD status after two consolidation cycles, and/or MRD-negative status lost at any time (molecular relapse), were redefined as high-risk patients and recommended for allo-HSCT as pre-emptive treatment. Thirteen molecular relapse patients who underwent allo-HSCT in CR1 as pre-emptive treatment were excluded in multivariate analysis in case of bias. Multivariate analysis of pre-treatment parameters showed that a low risk of NGS with a white blood cell count (WBC) of <20 × 109/L at diagnosis were favourable factors for CIR [hazard ratio (HR) = 0.67, 95% CI: 0.41–0.92, p = 0.048; HR = 0.54, 95% CI: 0.34–0.84, p = 0.002 respectively] and RFS (HR = 1.52, 95% CI: 1.01–2.47, p = 0.045; HR = 1.87, 95% CI: 1.19–2.91, p = 0.006 respectively), while a low risk of NGS was a favourable factor for OS (HR = 1.87, 95% CI: 1.11–3.67, p = 0.031). Multivariate analysis including pre-treatment and post-treatment parameters showed that a low risk of MRD was the only favourable factor for CIR (HR = 0.10, 95% CI: 0.06–0.18, p < 0.001), RFS (HR = 7.28, 95% CI: 4.48–11.78, p < 0.001), and OS (HR = 5.58, 95% CI: 2.84–10.73, p < 0.001) (Table 2). In 88 relapsed patients, 41 out of 76 patients (53.9%) achieved CR2 after induction. Nineteen CR2 and 10 non-remission patients underwent allo-HSCT and achieved a median survival time of 55 months (range 12–109) after relapse. Meanwhile, another 47 patients underwent a non-transplant treatment strategy as soon as relapse achieved a median survival time of 19 months (range 9–76) after relapse. The CR2 (5-year OS 89.2% vs. 26.4%; p = 0.001) and not reached (NR) (3-year OS, 67.5% vs. 19.4%; p = 0.009) patients after relapse who underwent allo-HSCT all achieved superior OS compared to non-transplant patients (Figure 2). The patients who underwent allo-HSCT, or not, after relapse were comparable with abnormal karyotype, FLT3-ITD mutation, or not, and age. In accordance with our previous study,7 we confirmed that combining pre- and post-treatment parameters is a rational way to improve outcome prediction in bi CEBPA AML. The results indicate that co-occurring mutations with a WBC count of >20 × 109/L at diagnosis in bi CEBPA have prognostic significance in the analysis of pre-treatment parameters. However, they were not the strongest factor predictors, especially compared with MRD risk stratification, when analysis of all factors included pre- and post-treatment. As with previous studies,1, 7 our results show that no OS benefits from allo-HSCT in CR1. However, 19 CR2 and 10 NR patients who underwent allo-HSCT achieved superior OS, calculated after relapse compared to non-transplant patients. The results are consistent with those of a European multicentre report8 and our previous single-centre report.7 This suggests that bi CEBPA mutations are predictive of a favourable outcome, and relapsed patients still have a favourable outcome followed by allo-HSCT. A limitation of our current study is that the patients were not randomised to receive chemotherapy or allo-HSCT. The patients who underwent allo-HSCT in CR1 were carrying a more abnormal karyotype, were more FLT3-ITD positive, and were younger than the non-transplant cohort. In summary, this multicentre study included a larger sample size and a longer follow-up period than our previous single-centre report.7 Patients without additional molecular mutations and with a GATA2 mutation were defined as “NGS low risk”, which was a favourable factor of CIR, RFS, and OS. Meanwhile, a WBC count of <20 × 109/L at diagnosis was a favourable factor of CIR and RFS in the analysis of pre-treatment parameters. A high risk of MRD was the only adverse factor of relapse and survival when all factors included pre-treatment and post-treatment. Relapsed patients still have a favourable outcome after reinduction, followed by allo-HSCT. These conclusions need further verification through prospective studies. The work was supported by "the National Key Research and Development Program of China" (2017YFA0104500), "the National Natural Science Foundation of China" (grant no. 81930004), "Innovative Research Groups of the National Natural Science Foundation of China" (grant no. 81621001), and "Capital Characteristic Clinic Project Foundation" (grant no. Z181100001718126).

Abstract:Hypomethylating agents (HMAs), such as azsacitidine (AZA), are considered the standard of care for patients with International Prognostic Scoring System (IPSS) Intermediate-2 (Int-2) or High-risk myelodysplastic syndrome (MDS) and chronic myelomonocytic leukaemia (CMML) who are not candidates for allogeneic stem cell transplantation (alloSCT) (Kantarjian et al, 2006; Silverman et al, 2006; Fenaux et al, 2009). Therapy with AZA prolongs overall survival (OS) in this group of patients (including acute myeloid leukaemia [AML] with 20–30% blasts).(Fenaux et al, 2009) Nevertheless, these agents are not curative, with a median OS of 5·6 months for patients that fail AZA therapy. (Prebet et al, 2011) Many centres have used HMAs as a bridge to alloSCT in MDS patients in an attempt to reduce tumour burden and prolong the time to AML progression. (Damaj et al, 2012) However, this strategy leaves patients at risk of AZA treatment failure, which may delay or prevent subsequent alloSCT. Recent data, in a very small number of patients, have demonstrated poor response rates to salvage therapy with intensive chemotherapy after AZA failure. (Prebet et al, 2011, 2012; Duong et al, 2013) This retrospective analysis evaluated the outcome of 18 patients with MDS, CMML and AML, who failed AZA therapy, whilst awaiting a donor to be found for alloSCT, and subsequently received induction chemotherapy (between 1 July, 2009 and 31 December, 2012) at the Princess Margaret Cancer Centre. Seventeen of these patients received AZA as a bridge to alloSCT, while awaiting a donor to be found. Inclusion criteria were: (i) diagnosis of AML with 20–30% blasts, MDS or CMML by the World Health Organization classification, (ii) IPSS Int-2 or High-risk disease (Greenberg et al, 1997), and (iii) at least 1 cycle of AZA received. For MDS and AML patients, responses were defined according to the International Working Group Criteria.(Cheson et al, 2003, 2006) Survival was calculated from the date of AZA failure, defined as the date of evaluation of response after the last cycle of AZA. Primary AZA failure was defined as the absence of any response to AZA and secondary AZA failure as disease progression after a first response. Kaplan-Meier curves and median survival times were used to summarize the OS and time to progression outcomes. Continuous patient demographics were summarized by their median and range, while categorical demographics were summarized by their frequency and proportion. Patient characteristics are listed in Table 1. Only one patient was over the age of 70 years. Of the 18 patients, 44% had secondary or therapy-related (s/t-) MDS or AML at the time of AZA therapy (including two patients who received a prior autologous SCT [autoSCT] for non-Hodgkin lymphoma and AML [different karyotype when developed MDS] and 1 an autoSCT followed by syngeneic alloSCT for multiple myeloma); 67% had IPSS poor-risk cytogenetics. Median number of AZA cycles received was 5·5 (range 1–18) with seven patients (39%) achieving a response (including one complete remission [CR], one marrow CR and haematological improvement [HI], and five HI). Nine patients were primary AZA failures and seven secondary AZA failures. No patients were intolerant of AZA. Two patients were taken off AZA after 1 cycle of therapy to receive induction chemotherapy as a human leucocyte antigen-identical donor was found. At the time of induction chemotherapy, 15 patients had s/t-AML (12 had progressed from MDS), two had refractory anaemia with excess blasts type 2 (RAEB-2), and one CMML-2. Two patients with AML received cytoreductive therapy prior to induction chemotherapy: 1 with single agent cytarabine followed by hydroxycarbamide and 1 with hydroxycarbamide alone. Cytogenetic risk, as defined by the Medical Research Council AML classification, was intermediate in 4 and poor in 11 patients, respectively. Induction chemotherapy regimens are listed in Table 2. The overall response rate was 50% and 43·8% in all patients and AZA failures only, respectively (Table 3). The CR rate was 22% and 25%, CR with incomplete platelet recovery (CRp) was 6% and 0%, CR with incomplete count recovery (CRi) was 17% and 12·5%, and morphological leukaemic-free state 17% and 6·3% in all patients and in AZA failures only, respectively. One patient in CRi relapsed after 2·5 months and achieved CR2 after salvage chemotherapy with mitoxantrone, etoposide and cytarabine (NOVE-HiDAc). All seven patients achieved a CR/CRp/CRi after one induction chemotherapy cycle; four of these patients had intermediate-risk and 1 poor-risk cytogenetics, with no karyotype results available for the remaining two patients. Three patients with AML who were primary refractory to initial daunorubicin and cytarabine induction failed to achieve a CR with NOVE-HiDAc salvage chemotherapy. Four patients died during induction. Response duration for patients who achieved a CR/CRi/CRp was 4 months (range, 1·7–9 months). Four of nine responders received an alloSCT, with the remaining five patients relapsing (three while awaiting an alloSCT). After a median follow-up of 5·2 months, 17 patients have died. The one surviving patient has been lost to follow-up 25 weeks after induction chemotherapy. There was no difference in OS between patients who received an alloSCT compared with those who did not (P = 0·55). All four patients who received an alloSCT died: two from relapsed AML, one from graft-versus-host disease and one from progressive respiratory failure. Median OS for all patients was 6·2 months (Fig 1). Median OS for patients who achieved a CR/CRi/CRp was 11·1 months, after a median follow-up of 10·2 months. No pretreatment variables were associated with improved OS or likelihood of achieving a CR, although the patient numbers were small. Contrary to prior reports (Prebet et al, 2011, 2012), our results demonstrate that induction chemotherapy can yield responses in a significant number of patients who have failed AZA therapy. However, response duration and OS remain poor for AZA treatment failures. Therefore, despite retrospective studies suggesting that it is not detrimental to receive hypomethylating agents prior to alloSCT (Damaj et al, 2012), one should not delay alloSCT for eligible patients with IPSS Int-2 and High–risk MDS until a loss or lack of response to AZA is observed. For those transplant-eligible patients who have a donor and may require tumour burden reduction prior to alloSCT, induction chemotherapy may be preferable to AZA. Patients who fail AZA therapy should be enrolled onto clinical trials. KWLY treated patients, conceived research, collected and analysed data and wrote the manuscript. JB, ADS, VG, MDM and ACS treated patients and participated in writing of the manuscript. RDB and WX analysed the data. KWLY, JB, and ACS received honoraria from Celgene; KWLY and ACS received research support from Celgene. The remaining authors declare no conflict of interest.

Long-Term Follow-up of AML Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation after Primary Induction Failure

Long-term follow-up of patients with acute myeloid leukemia undergoing allogeneic hematopoietic stem cell transplantation after primary induction failure

Efficacy of Allogeneic Hematopoietic Stem Cell Transplantation in Intermediate-Risk Acute Myeloid Leukemia Adult Patients in First Complete Remission: A Meta-Analysis of Prospective Studies.

The Impact Of Allogeneic Hematopoietic Stem-Cell Transplantation On Outcome Of The Patients With Intermediate-Risk Acute Myeloid Leukemia

S238: MATCHED RELATED VERSUS UNRELATED VERSUS HAPLOIDENTICAL DONORS FOR ALLOGENEIC TRANSPLANTATION IN AML PATIENTS ACHIEVING FIRST COMPLETE REMISSION AFTER TWO INDUCTION COURSES: A STUDY FROM THE ALWP/EBMT

Prognostic Implications of the Detection of Measurable Residual Disease and Mutations Based on Next‐generation Sequencing in Acute Myeloid Leukaemia with Biallelic Mutations of CEBPA

Allogeneic Hematopoietic Stem Cell Transplantation (HCT) in First Remission Improves Outcome Irrespective of FLT3-ITD Allelic Burden Among Patients with Acute Myeloid Leukemia and FLT3-ITD Mutation

Long-Term Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma

Trends in allogeneic transplantation for favorable risk acute myeloid leukemia in first remission: a longitudinal study of > 15 years from the ALWP of the EBMT

Successful Result Of 113 Patients For Refractory/Recurrent Leukemia By Allogeneic Hematopoietic Cell Transplantation And Prophylactic Immunotherapy

Rapid Risk-Profiling Including Fast Donor Search within a Multi-Center Trial Allows for Early Allogeneic Stem Cell Transplantation during Aplasia in Patients with High-Risk Acute Myeloid Leukemia.

Allogeneic hematopoietic cell transplantation with sequential conditioning regimen in relapsed refractory acute myeloid leukemia

Long-term follow-up of allogeneic hematopoitic stem cell transplantation for patients with chronic myeloid leukemia

Decision Analysis of Allogeneic Hematopoietic Stem Cell Transplantation Versus Chemotherapy in Cytogenetically Standard-Risk Acute Myeloid Leukemia in First Complete Remission: The Impact of FLT3-ITD Profile

A Multi-Center Retrospective Analysis of Outcomes Post Allogeneic Stem Cell Transplantation in AML Patients with TET2 Mutations: A Study on Behalf of the Global Committee and the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation

Effect of disease status prior to T-cell depleted allogeneic stem cell transplantation on relapse-free and overall survival in patients with adverse-risk acute myeloid leukemia (AML).

Salvage Induction Chemotherapy after Azacitdine Treatment Failure in Patients Who Received Azacitidine As a Bridge to Allogeneic Stem Cell Transplantation

Early allogeneic transplantation favorably influences the outcome of adult patients suffering from acute myeloid leukemia

Prognostic Effect and Clinical Application of Early Measurable Residual Disease (MRD) By Flow Cytometry on De Novo Acute Myeloid Leukemia (AML)

Autologous Stem Cell Transplantation in Adult Patients with Intermediate-Risk Acute Myeloid Leukemia in First Complete Remission and No Detectable Minimal Residual Disease. A Comparative Retrospective Study with Haploidentical Transplants of the Global Committee and the ALWP of the EBMT

Flow cytometry-based measurable residual disease (MRD) analysis identifies AML patients who may benefit from allogeneic hematopoietic stem cell transplantation